Also in this playlist...
This transcript is automatically generated
Maker Allergan reporting higher than expected quarterly earnings today and joining us now.
In a Fox Business interview is David -- he is Allergan chairman president and CEO what.
Got a lot of your plate and there -- -- -- good to have again David thanks for coming -- let's I I know you're more than a one trick by your your more than Botox but everybody focuses on Botox.
Particularly wondering how.
This particular drug which has sold for your company might be affected by the health care law and everybody knows that -- for -- wrinkle treatment but it also works for migraine headaches.
Overactive bladder and a couple of other things as well some of those would be covered by insurance and by extension by Medicaid and Medicare.
Would this new law but -- I'm guessing the -- stuff would not be affected correct.
That is -- you have to pay out of pocket.
Absolutely correct -- Roughly last year the -- of -- talks worldwide was roughly 50% for the very famous Botox cosmetic.
And all the rest the other 50%.
Now therapeutic David forgive me for being suspicious but is it conceivable that say I have some wrinkles and wanna get -- I could get a doctor decide a prescription for Botox for a migraine that didn't really exist and use the drug.
For my wrinkles.
-- that's almost impossible because the doses are completely different.
For the infamous lines here you need to twenty units and from my -- It's such a 155.
-- -- seven times the amount.
Friendly of course the wrinkles should normally be treated by dermatologists.
To for -- clearly you go to neurologist.
And David where most of is no Botox your product -- beauty purposes you remove wrinkles to make us improve the way we look at what.
Whenever it may be I'd be seen is a luxury especially during tough economic times like this.
That seems like you guys are faring so well how do you how do you rationalize that.
Well I think come for a long time we've seen that people really.
-- great value on their appearance on to even jury in the Great Recession people.
Really unless they were in terrible trouble didn't stop.
The most they stretched out the treatments between the various.
We've obviously watch this very carefully to.
The loss a couple of weeks there was nervousness around luxury goods spending but I think we could show today you know I I remarked aid.
In local currencies constant currency -- talks grew 14%.
Q2 over Q2.
And are reported worldwide that both therapeutic.
As well those cosmetic grew double digit in local currencies so the consumer is alive and well both here in the US.
And in Europe not -- David that the holy Grail if you will for for cosmetic -- drug companies is is baldness treatment of baldness.
You have you have a drug let TC is it is my pronouncing your right.
What's what's the latest qualities.
When we get a full market penetration veteran.
OK well forceful with -- is indicated for insufficient.
Length thickness and darkness of eyelashes so that's our contribution.
Again -- -- -- Goldman furthers -- could it not actually eventually treat baldness.
Dot strike and so we're in.
Clinical trials right now both these trials have fully enrolled in phase two.
Not only for male baldness because of course we males are very conscious.
Of the thinning problems that most of us suffer from.
But I actually female baldness has probably us important and -- costs the ladies -- actually do something about it.
So we're gonna get a read thoughts about not and we.
Plan to publish the results of the present to -- to medical convention.
Our nightly at that -- he's a very very popular product with the lady is that thank you so much David Piet Allergan CEO thanks David appreciated.
Thank you --
Filter by section